Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Application of epigenetic data in human health risk assessment.

Cote IL, McCullough SD, Hines RN, Vandenberg JJ.

Curr Opin Toxicol. 2017 Nov 6;6:71-78. doi: 10.1016/j.cotox.2017.09.002.

PMID:
29333520
2.

Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages.

Song G, Sun X, Hines RN, McCarver DG, Lake BG, Osimitz TG, Creek MR, Clewell HJ, Yoon M.

Drug Metab Dispos. 2017 May;45(5):468-475. doi: 10.1124/dmd.116.074583. Epub 2017 Feb 22.

3.

FutureTox III: Bridges for Translation.

Juberg DR, Knudsen TB, Sander M, Beck NB, Faustman EM, Mendrick DL, Fowle JR 3rd, Hartung T, Tice RR, Lemazurier E, Becker RA, Fitzpatrick SC, Daston GP, Harrill A, Hines RN, Keller DA, Lipscomb JC, Watson D, Bahadori T, Crofton KM.

Toxicol Sci. 2017 Jan;155(1):22-31. doi: 10.1093/toxsci/kfw194. Epub 2016 Oct 25.

PMID:
27780885
4.

Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models.

Marek E, Momper JD, Hines RN, Takao CM, Gill JC, Pravica V, Gaedigk A, Burckart GJ, Neville KA.

J Pediatr Pharmacol Ther. 2016 May-Jun;21(3):224-32. doi: 10.5863/1551-6776-21.3.224.

5.

Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards.

El-Masri H, Kleinstreuer N, Hines RN, Adams L, Tal T, Isaacs K, Wetmore BA, Tan YM.

Toxicol Sci. 2016 Jul;152(1):230-43. doi: 10.1093/toxsci/kfw082. Epub 2016 May 4.

6.

Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver.

Thomson MM, Hines RN, Schuetz EG, Meibohm B.

Drug Metab Dispos. 2016 Jul;44(7):999-1004. doi: 10.1124/dmd.115.069252. Epub 2016 Apr 20.

7.

Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.

Giebel NL, Shadley JD, McCarver DG, Dorko K, Gramignoli R, Strom SC, Yan K, Simpson PM, Hines RN.

Drug Metab Dispos. 2016 Jul;44(7):1027-37. doi: 10.1124/dmd.116.069344. Epub 2016 Feb 26.

8.

Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny.

Hines RN, Simpson PM, McCarver DG.

Drug Metab Dispos. 2016 Jul;44(7):959-66. doi: 10.1124/dmd.115.068957. Epub 2016 Jan 29.

9.

Baseline Chromatin Modification Levels May Predict Interindividual Variability in Ozone-Induced Gene Expression.

McCullough SD, Bowers EC, On DM, Morgan DS, Dailey LA, Hines RN, Devlin RB, Diaz-Sanchez D.

Toxicol Sci. 2016 Mar;150(1):216-24. doi: 10.1093/toxsci/kfv324. Epub 2015 Dec 29.

10.

Oxidative stress-responsive transcription factor NRF2 is not indispensable for the human hepatic Flavin-containing monooxygenase-3 (FMO3) gene expression in HepG2 cells.

Rudraiah S, Gu X, Hines RN, Manautou JE.

Toxicol In Vitro. 2016 Mar;31:54-9. doi: 10.1016/j.tiv.2015.11.016. Epub 2015 Nov 23.

11.

Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.

Sethi PK, White CA, Cummings BS, Hines RN, Muralidhara S, Bruckner JV.

Pediatr Res. 2016 Mar;79(3):409-15. doi: 10.1038/pr.2015.237. Epub 2015 Nov 16.

PMID:
26571224
12.

Use of the RISK21 roadmap and matrix: human health risk assessment of the use of a pyrethroid in bed netting.

Doe JE, Lander DR, Doerrer NG, Heard N, Hines RN, Lowit AB, Pastoor T, Phillips RD, Sargent D, Sherman JH, Young Tanir J, Embry MR.

Crit Rev Toxicol. 2016;46(1):54-73. doi: 10.3109/10408444.2015.1082974. Epub 2015 Oct 30. Review.

13.

Raising the bar for reproducible science at the U.S. Environmental Protection Agency Office of Research and Development.

George BJ, Sobus JR, Phelps LP, Rashleigh B, Simmons JE, Hines RN; Community of Practice for Statistics Guidance Documents Working Groups.

Toxicol Sci. 2015 May;145(1):16-22. doi: 10.1093/toxsci/kfv020. Epub 2015 Mar 19.

14.

Risk assessment in the 21st century: roadmap and matrix.

Embry MR, Bachman AN, Bell DR, Boobis AR, Cohen SM, Dellarco M, Dewhurst IC, Doerrer NG, Hines RN, Moretto A, Pastoor TP, Phillips RD, Rowlands JC, Tanir JY, Wolf DC, Doe JE.

Crit Rev Toxicol. 2014 Aug;44 Suppl 3:6-16. doi: 10.3109/10408444.2014.931924. Review.

PMID:
25070414
15.

A 21st century roadmap for human health risk assessment.

Pastoor TP, Bachman AN, Bell DR, Cohen SM, Dellarco M, Dewhurst IC, Doe JE, Doerrer NG, Embry MR, Hines RN, Moretto A, Phillips RD, Rowlands JC, Tanir JY, Wolf DC, Boobis AR.

Crit Rev Toxicol. 2014 Aug;44 Suppl 3:1-5. doi: 10.3109/10408444.2014.931923. Review.

PMID:
25070413
16.

Human hepatic UGT2B15 developmental expression.

Divakaran K, Hines RN, McCarver DG.

Toxicol Sci. 2014 Sep;141(1):292-9. doi: 10.1093/toxsci/kfu126. Epub 2014 Jun 30.

17.

Tolerance to acetaminophen hepatotoxicity in the mouse model of autoprotection is associated with induction of flavin-containing monooxygenase-3 (FMO3) in hepatocytes.

Rudraiah S, Rohrer PR, Gurevich I, Goedken MJ, Rasmussen T, Hines RN, Manautou JE.

Toxicol Sci. 2014 Sep;141(1):263-77. doi: 10.1093/toxsci/kfu124. Epub 2014 Jun 27.

18.

Toll-like receptor genetic variants are associated with Gram-negative infections in VLBW infants.

Sampath V, Mulrooney NP, Garland JS, He J, Patel AL, Cohen JD, Simpson PM, Hines RN.

J Perinatol. 2013 Oct;33(10):772-7. doi: 10.1038/jp.2013.80. Epub 2013 Jul 18.

19.

Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.

Sharma S, Ellis EC, Gramignoli R, Dorko K, Tahan V, Hansel M, Mattison DR, Caritis SN, Hines RN, Venkataramanan R, Strom SC.

Drug Metab Dispos. 2013 Feb;41(2):296-304. doi: 10.1124/dmd.112.044891. Epub 2012 Nov 5.

20.

Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.

Hines RN.

Int J Pharm. 2013 Aug 16;452(1-2):3-7. doi: 10.1016/j.ijpharm.2012.05.079. Epub 2012 Jul 3. Review.

PMID:
22766445
21.

A TLR5 (g.1174C > T) variant that encodes a stop codon (R392X) is associated with bronchopulmonary dysplasia.

Sampath V, Garland JS, Le M, Patel AL, Konduri GG, Cohen JD, Simpson PM, Hines RN.

Pediatr Pulmonol. 2012 May;47(5):460-8. doi: 10.1002/ppul.21568. Epub 2011 Nov 4.

PMID:
22058078
22.

Prenatal and postnatal expression of glutathione transferase ζ 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate.

Li W, Gu Y, James MO, Hines RN, Simpson P, Langaee T, Stacpoole PW.

Drug Metab Dispos. 2012 Feb;40(2):232-9. doi: 10.1124/dmd.111.041533. Epub 2011 Oct 25.

23.

The NFKB1 (g.-24519delATTG) variant is associated with necrotizing enterocolitis (NEC) in premature infants.

Sampath V, Le M, Lane L, Patel AL, Cohen JD, Simpson PM, Garland JS, Hines RN.

J Surg Res. 2011 Jul;169(1):e51-7. doi: 10.1016/j.jss.2011.03.017. Epub 2011 Apr 1.

PMID:
21529841
24.

Human and environmental health challenges for the next decade (2010–2020).

Bonnefoi MS, Belanger SE, Devlin DJ, Doerrer NG, Embry MR, Fukushima S, Harpur ES, Hines RN, Holsapple MP, Kim JH, MacDonald JS, O'Lone R, Pettit SD, Stevens JL, Takei AS, Tinkle SS, van der Laan JW.

Crit Rev Toxicol. 2010 Nov;40(10):893-911. doi: 10.3109/10408444.2010.506640. Review.

PMID:
20854192
25.

Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

Hines RN, Sargent D, Autrup H, Birnbaum LS, Brent RL, Doerrer NG, Cohen Hubal EA, Juberg DR, Laurent C, Luebke R, Olejniczak K, Portier CJ, Slikker W.

Toxicol Sci. 2010 Jan;113(1):4-26. doi: 10.1093/toxsci/kfp217. Epub 2009 Sep 21. Review.

26.

Human hepatic CYP2B6 developmental expression: the impact of age and genotype.

Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E.

Biochem Pharmacol. 2009 Jul 15;78(2):184-90. doi: 10.1016/j.bcp.2009.03.029. Epub 2009 Apr 5.

PMID:
19464434
27.

Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer-binding protein beta (C/EBPbeta) liver inhibitory and liver activating proteins.

Klick DE, Shadley JD, Hines RN.

Biochem Pharmacol. 2008 Jul 15;76(2):268-78. doi: 10.1016/j.bcp.2008.05.002. Epub 2008 May 7.

PMID:
18555208
28.

Developmental changes in human liver CYP2D6 expression.

Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Divakaran K, Le M, Hines RN.

Drug Metab Dispos. 2008 Aug;36(8):1587-93. doi: 10.1124/dmd.108.021873. Epub 2008 May 12.

29.

Regulatory polymorphisms and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition.

Hines RN, Koukouritaki SB, Poch MT, Stephens MC.

Drug Metab Rev. 2008;40(2):263-301. doi: 10.1080/03602530801952682 . Review.

PMID:
18464046
30.

The ontogeny of drug metabolism enzymes and implications for adverse drug events.

Hines RN.

Pharmacol Ther. 2008 May;118(2):250-67. doi: 10.1016/j.pharmthera.2008.02.005. Epub 2008 Mar 5. Review.

PMID:
18406467
31.

Novel CYP2C9 promoter variants and assessment of their impact on gene expression.

Kramer MA, Rettie AE, Rieder MJ, Cabacungan ET, Hines RN.

Mol Pharmacol. 2008 Jun;73(6):1751-60. doi: 10.1124/mol.107.044149. Epub 2008 Feb 29.

32.

Ontogeny of human hepatic cytochromes P450.

Hines RN.

J Biochem Mol Toxicol. 2007;21(4):169-75. Review.

PMID:
17936930
33.

Mechanisms regulating human FMO3 transcription.

Klick DE, Hines RN.

Drug Metab Rev. 2007;39(2-3):419-42.

PMID:
17786630
34.

Identification and functional analysis of a novel human CYP2E1 far upstream enhancer.

Shadley JD, Divakaran K, Munson K, Hines RN, Douglas K, McCarver DG.

Mol Pharmacol. 2007 Jun;71(6):1630-9. Epub 2007 Mar 12.

35.

Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants.

Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, Krueger SK, VanDyke JE, Williams DE, Pajewski NM, Wang T, Hines RN.

J Pharmacol Exp Ther. 2007 Jan;320(1):266-73. Epub 2006 Oct 18.

36.

Epirubicin glucuronidation and UGT2B7 developmental expression.

Zaya MJ, Hines RN, Stevens JC.

Drug Metab Dispos. 2006 Dec;34(12):2097-101. Epub 2006 Sep 19.

37.

Pharmacogenomics and the future of drug therapy.

Hines RN, McCarver DG.

Pediatr Clin North Am. 2006 Aug;53(4):591-619. Review.

PMID:
16872995
38.

Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3.

Hines RN.

Expert Opin Drug Metab Toxicol. 2006 Feb;2(1):41-9. Review.

PMID:
16863467
39.

Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450.

Vyas PM, Roychowdhury S, Khan FD, Prisinzano TE, Lamba J, Schuetz EG, Blaisdell J, Goldstein JA, Munson KL, Hines RN, Svensson CK.

J Pharmacol Exp Ther. 2006 Oct;319(1):488-96. Epub 2006 Jul 20.

40.

Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases.

Vyas PM, Roychowdhury S, Koukouritaki SB, Hines RN, Krueger SK, Williams DE, Nauseef WM, Svensson CK.

J Pharmacol Exp Ther. 2006 Oct;319(1):497-505. Epub 2006 Jul 20.

41.

Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Yang F, Tong X, McCarver DG, Hines RN, Beard DA.

J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):485-518. Epub 2006 Jun 7.

PMID:
16758333
42.

A tiered approach to life stages testing for agricultural chemical safety assessment.

Cooper RL, Lamb JC, Barlow SM, Bentley K, Brady AM, Doerrer NG, Eisenbrandt DL, Fenner-Crisp PA, Hines RN, Irvine LF, Kimmel CA, Koeter H, Li AA, Makris SL, Sheets LP, Speijers G, Whitby KE.

Crit Rev Toxicol. 2006 Jan;36(1):69-98. Review.

PMID:
16708695
43.

The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines.

Krueger SK, Vandyke JE, Williams DE, Hines RN.

Drug Metab Rev. 2006;38(1-2):139-47. Review.

PMID:
16684653
44.

Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.

Nong A, McCarver DG, Hines RN, Krishnan K.

Toxicol Appl Pharmacol. 2006 Jul 1;214(1):78-87. Epub 2006 Feb 7.

PMID:
16464483
45.

Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver.

Duanmu Z, Weckle A, Koukouritaki SB, Hines RN, Falany JL, Falany CN, Kocarek TA, Runge-Morris M.

J Pharmacol Exp Ther. 2006 Mar;316(3):1310-7. Epub 2005 Dec 9.

46.

Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development.

Koukouritaki SB, Hines RN.

Pharmacogenomics. 2005 Dec;6(8):807-22. Review.

PMID:
16296944
47.

Molecular mechanisms regulating human CYP4B1 lung-selective expression.

Poch MT, Cutler NS, Yost GS, Hines RN.

Drug Metab Dispos. 2005 Aug;33(8):1174-84. Epub 2005 May 17.

48.

Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.

Krueger SK, Siddens LK, Henderson MC, Andreasen EA, Tanguay RL, Pereira CB, Cabacungan ET, Hines RN, Ardlie KG, Williams DE.

Pharmacogenet Genomics. 2005 Apr;15(4):245-56.

49.

Sp1 and Sp3 regulate basal transcription of the human CYP2F1 gene.

Wan J, Carr BA, Cutler NS, Lanza DL, Hines RN, Yost GS.

Drug Metab Dispos. 2005 Aug;33(8):1244-53. Epub 2005 Apr 28.

50.

Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants.

Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, Hines RN.

Mol Pharmacol. 2005 Aug;68(2):383-92. Epub 2005 Apr 27.

Supplemental Content

Loading ...
Support Center